Ninita Brown, MD
Ophthalmology · Newnan, GANPI 1891937322
Payments from drug & device makers
Across 254 payments — averaging $75.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$8K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$2K
- Alcon$1K
- Glaukos Corporation$878
- Aerie Pharmaceuticals, Inc.$644
- plus $5K from 29 others
What the payments were for
- Food & beverage$11,58960%
- Gifts$640%
- Other$7,50339%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 3 | $7,628 |
| AbbVie(2 entities) | 66 | $2,369 |
| Sun Pharmaceutical Industries Inc. | 37 | $1,902 |
| Alcon | 28 | $1,225 |
| Glaukos Corporation | 10 | $878 |
| Aerie Pharmaceuticals, Inc. | 10 | $644 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $599 |
| Genentech USA, Inc. | 3 | $391 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $363 |
| Novartis | 16 | $346 |
| Rxsight Inc | 3 | $288 |
| Amgen(2 entities) | 3 | $267 |
| Ivantis, Inc | 3 | $262 |
| Sight Sciences, Inc. | 7 | $260 |
| Bausch & Lomb Americas Inc. | 5 | $222 |
| Thea Pharma Inc. | 6 | $176 |
| NEW World Medical,inc. | 2 | $173 |
| Eyevance Pharmaceuticals LLC | 1 | $172 |
| Eyepoint US, Inc. | 2 | $148 |
| Tarsus Pharmaceuticals, Inc. | 1 | $145 |
| Carl Zeiss Meditec, Inc. | 1 | $134 |
| Regeneron Healthcare Solutions, Inc. | 1 | $110 |
| Kala Pharmaceuticals, Inc. | 5 | $105 |
| Shire North American Group Inc | 1 | $77 |
| Akorn Operating Company LLC | 2 | $47 |
| Iridex Corporation | 3 | $38 |
| Dompe US, Inc. | 2 | $37 |
| Oyster Point Pharma, Inc. | 2 | $34 |
| Boston Scientific | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| GSK | 1 | $18 |
| Mirum Pharmaceuticals, Inc. | 1 | $17 |
| Omeros Corporation | 1 | $15 |
| Akorn, Inc. | 1 | $15 |
| Biotissue Holdings Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA$7,503
- CEQUA$987
- Rocklatan$647
- BROMSITE$372
- Rhopressa$368
- XELPROS$250
- TEPEZZA$245
- VABYSMO$245
- Tecnis IOL$240
- Hydrus$237
- DURYSTA$230
- LUMIGAN$216
- Tobradex ST$172
- iStent Trabecular Micro-Bypass System Model iS3$160
- KXL System$156
- Photrexa$156
- iStent inject W$149
- OMNI(R) SURGICAL SYSTEM (US)$149
- Centurion$147
- XDEMVY$145
How this compares
$19,157 in reported general payments places this provider in the 85th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 211 | $126,772 |
| RestasisCyclosporine | 69 | $94,804 |
| CombiganBrimonidine Tartrate/Timolol | 135 | $57,168 |
| RhopressaNetarsudil Mesylate | 85 | $52,393 |
| RocklatanNetarsudil Mesylat/Latanoprost | 79 | $46,016 |
| Latanoprost | 1,716 | $22,615 |
| VyzultaLatanoprostene Bunod | 37 | $22,289 |
| Alphagan PBrimonidine Tartrate | 41 | $21,569 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 80 | $21,259 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,034 | $20,524 |
| Cyclosporine | 35 | $19,859 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 53 | $17,361 |
| Brimonidine Tartrate | 550 | $16,279 |
| Prednisolone Acetate | 266 | $11,344 |
| Travoprost | 43 | $10,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,369 | $300,313456 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $644 | $98,409164 claims |
| AlconSimbrinza, Azopt | $1,225 | $25,67268 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $222 | $22,28937 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $363 | $10,02429 claims |
| Thea Pharma Inc.Iyuzeh | $176 | $6,86313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Newnan
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.